Claudio L.
- Country
- Italy
- Department
- Medical Oncology Unit
Research Overview
- Pumitamig and Combination Therapy Versus Bevacizumab and Combination Therapy in Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- Phase III Study of Rilvegostomig plus Combination Chemotherapy versus Durvalumab plus Combination Chemotherapy in Patients with Advanced Biliary Tract Cancer
- Randomized Phase 3 Study of Precemtabart Tocentecan With or Without Bevacizumab Versus Trifluridine/Tipiracil + Bevacizumab in Treated Metastatic Colorectal Cancer
Data & Insights
Has run more than one trial at 131 of 321 partner sites.
Specializations
Colorectal Cancer Treatment
This investigator specializes in the treatment of metastatic colorectal cancer, with particular emphasis on developing innovative therapeutic approaches for patients with advanced disease stages.
- RAS/BRAF wild-type tumors
- Left-sided colorectal cancer
- Unresectable metastatic disease
Their research encompasses both first-line and subsequent treatment strategies for metastatic colorectal cancer patients.
Targeted Therapies
The investigator focuses on evaluating targeted therapeutic combinations, particularly involving monoclonal antibodies and immunotherapy approaches.
- Cetuximab-based treatments
- Immunotherapy combinations
- Biomarker-driven therapies
Their work includes investigation of continuous versus intermittent treatment approaches in targeted therapy regimens.
Precision Medicine
The investigator conducts research in biomarker-driven treatment strategies and personalized medicine approaches for colorectal cancer.
- Liquid biopsy applications
- Molecular profiling
- Treatment resistance patterns
Their research includes evaluation of both tissue and blood-based biomarkers for treatment selection and monitoring.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.